<DOC>
	<DOCNO>NCT01113320</DOCNO>
	<brief_summary>Approximately twenty four ( 24 ) subject participate research trial . The research trial conduct approximately twelve ( 12 ) medical center follow country : Germany , France , South Africa , Austria Canada . The research trial last December 2011 .</brief_summary>
	<brief_title>Safinamide Levodopa Induced Dyskinesia Parkinson 's Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . The subject give his/her write informed consent participate trial . 2 . The subject present diagnosis idiopathic Parkinson 's disease accord United Kingdom ( UK ) Parkinson 's Disease Society Brain Bank Clinical Diagnosis Criteria 3 . The subject outpatient age 30 year . 4 . PD subject Hoehn Yahr disease stag IIIV ( ON state ) . 5 . PD subject experience levodopa induce dyskinesia , specifically predictable peakdose dyskinesia . 6 . Peakdose dyskinesia must consider subject problematic and/or disabling . 7 . Peakdose dyskinesia must warrant medical treatment Investigator 's opinion . 8 . The subject participate successfully diarycard training session . 9 . In judgment Investigator base subject 's history , previous treatment , clinical presentation , subject consider optimally treat screening ( i.e. , adjustment current medication improve subject 's symptom Parkinson 's disease ) . 10 . Stable dose PD drug least 4 week Screening Visit . This may include : levodopa dopamine agonist , cortho methyl transferase ( COMT ) inhibitor , anticholinergic . 11 . The dose levodopa PD drug use trial must remain unchanged throughout trial . 12 . Female subject must neither pregnant breastfeeding must lack childbearing potential , define either : 1. either post menopausal least 2 year , surgically sterilise undergone hysterectomy , 2. child bear potential , willing avoid pregnancy use adequate method contraception four week prior , four week last dose trial medication . For purpose trial , woman childbearing potential define female subject puberty unless postmenopausal least two year , surgically sterile sexually inactive . 13 . The subject show adequate compliance schedule intake trial medication completion diary . 1 . The subject participate safinamide clinical trial . 2 . The subject experience exclusively diphasic , state , myoclonic , dystonic , akathetic dyskinesia without peak dose dyskinesia . 3 . ( For female subject ) The subject pregnant lactating . 4 . Treatment MAOB inhibitor within eight week prior screen visit . 5 . Treatment amantadine four week prior screen visit budipine eight week prior screen visit . 6 . Treatment opioids ( e.g. , tramadol , meperidine derivative ) , serotonin norepinephrine reuptake inhibitor ( SNRIs ) ( e.g . venlafaxine , duloxetine ) , tri tetracyclic antidepressant , past 8 week prior screen visit . Dextromethorphan permit used treating cough . 7 . The subject receive neurosurgical intervention relate PD ( e.g . deep brain stimulation , thalamotomy etc . ) schedule trial period . 8 . Current clinically significant gastrointestinal , renal , hepatic , endocrine , pulmonary cardiovascular disease , include acute gastric ulcer , hypertension well control , asthma , chronic obstructive pulmonary disease ( COPD ) , unstable Type I diabetes . Subjects history gastric ulcer recent episode acute gastritis currently experience gastric pain eligible inclusion . 9 . Neoplastic disorder , either currently active remission less one year . 10 . Diagnosis HIV , positive test Hepatitis C antibody , Hepatitis B surface antigen . 11 . Concomitant disease likely interfere trial medication ( e.g . capable alter absorption , metabolism , elimination trial drug ) . 12 . The subject clinically significant illness , Investigator 's opinion , might interfere subject 's ability participate trial . 13 . Second thirddegree atrioventricular block sick sinus syndrome , uncontrolled atrial fibrillation , severe unstable angina , congestive heart failure , myocardial infarction within 3 month screen visit , significant ECG abnormality , include correct QT interval ( QTc ) 450 msec ( male ) 470 msec ( female ) , QTc base Bazett 's correction method . 14 . Ophthalmologic history include follow condition : albino subject , family history hereditary retinal disease , progressive and/or severe diminution visual acuity ( i.e. , 20/70 ) , retinitis pigmentosa , retinal pigmentation due cause , active retinopathy ocular inflammation ( uveitis ) , diabetic retinopathy 15 . The subject suffering dementia psychiatric illness prevents him/her give informed consent , i.e . Montreal Cognitive Assessment ( MoCA ) &lt; 23 point . 16 . Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) . 17 . Known hypersensitivity trial treatment ( ) , include placebo comparator drug ( ) . 18 . The subject legal incapacity limited legal capacity . 19 . The subject participate another clinical trial do within past 30 day 20 . Treatment drug hepatotoxic potential , e.g. , tamoxifen , within 4 week , receive radiation therapy drug cytotoxic potential , e.g , chemotherapy , within one year prior screen visit . 21 . Subjects current diagnosis substance abuse ( DSMIV ) history alcohol drug abuse past three month .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Safinamide - Parkinson 's disease - Levodopa induce dyskinesia</keyword>
	<keyword>Advanced idiopathic PD patient treat L-dopa suffer temporally predictable L-dopa induced peak-dose dyskinesia .</keyword>
</DOC>